Trial Profile
Phase 3 study on combinational therapy of SMP-508 with metformin in patients with type 2 diabetes mellitus.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 May 2016
Price :
$35
*
At a glance
- Drugs Repaglinide (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Sumitomo Dainippon Pharma
- 28 Feb 2013 The Japanese regulatory authorities approved the use of repaglinide in combination with biguanides as a treatment for type 2 diabetic patients based on results from this trial according to a Dainippon Sumitomo Pharma media release.
- 17 Apr 2012 Primary endpoint' has been met, according to a Dainippon Sumitomo Pharma media release.
- 17 Apr 2012 Status changed from recruiting to completed, according to a Dainippon Sumitomo Pharma media release.